Osteodystrophy in Chronic Liver Diseases

Overview

Journal Intern Emerg Med

Publisher Springer

Specialties Emergency Medicine
General Medicine

Date 2012 Jan 14

PMID 22241574

Citations 4

Authors

Pasquale Mansueto

Antonio Carroccio

Aurelio Seidita

Gaetana Di Fede

Antonio Craxi

Affiliations

Soon will be listed here.

Abstract

Osteoporosis and osteomalacia are, to date, among the most common metabolic diseases in the world. Lately, an association between metabolic bone diseases and chronic liver disease has been increasingly reported, inducing many authors to create a new nosographic entity known as 'hepatic osteodystrophy.' The importance of such a condition is further increased by the morbidity of these two diseases, which greatly reduce the quality of life because of frequent fractures, especially vertebral and femoral neck ones. For this reason, early identification of high-risk patients should be routinely performed by measuring bone mass density. The explanation for the association between bone diseases and chronic liver disease is still uncertain, and involves many factors: from hypogonadism to use of corticosteroid drugs, from genetic factors to interferon therapy. To date, few studies have been conducted, and all with a small number of patients to establish definitive conclusions about the possible treatment, but some evidence is beginning to emerge about the safety and efficacy of bisphosphonates.

Citing Articles

Bone microarchitecture and bone turnover in hepatic cirrhosis.

Wakolbinger R, Muschitz C, Scheriau G, Bodlaj G, Kocijan R, Feichtinger X Osteoporos Int. 2019; 30(6):1195-1204.

PMID: 30788527 PMC: 6546655. DOI: 10.1007/s00198-019-04870-6.

Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-γ-Glutamyl Transpeptidase Antibody.

Kawazoe Y, Miyauchi M, Nagasaki A, Furusho H, Yanagisawa S, Chanbora C PLoS One. 2015; 10(9):e0139620.

PMID: 26418133 PMC: 4587927. DOI: 10.1371/journal.pone.0139620.

Hepatic osteodystrophy.

Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M Clin Cases Miner Bone Metab. 2015; 11(3):185-91.

PMID: 25568651 PMC: 4269141.

Modeling hepatic osteodystrophy in Abcb4 deficient mice.

Hochrath K, Ehnert S, Ackert-Bicknell C, Lau Y, Schmid A, Krawczyk M Bone. 2013; 55(2):501-11.

PMID: 23545228 PMC: 4075965. DOI: 10.1016/j.bone.2013.03.012.

References

Cockayne S, Adamson J, Lanham-New S, Shearer M, Gilbody S, Torgerson D . Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166(12):1256-61. DOI: 10.1001/archinte.166.12.1256. View

Collier J, Ninkovic M, Compston J . Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002; 50 Suppl 1:i1-9. PMC: 1867644. DOI: 10.1136/gut.50.suppl_1.i1. View

Zein C, Jorgensen R, Clarke B, Wenger D, Keach J, Angulo P . Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005; 42(4):762-71. DOI: 10.1002/hep.20866. View

Dontas I, Yiannakopoulos C . Risk factors and prevention of osteoporosis-related fractures. J Musculoskelet Neuronal Interact. 2007; 7(3):268-72. View

Pazianas M, Miller P, Blumentals W, Bernal M, Kothawala P . A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29(8):1548-58. DOI: 10.1016/j.clinthera.2007.08.008. View

Boone R, Cheung A, Girlan L, Heathcote E . Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci. 2006; 51(6):1103-12. DOI: 10.1007/s10620-006-8015-x. View

Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S . Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol. 2005; 42(4):573-7. DOI: 10.1016/j.jhep.2004.11.035. View

Solaymani-Dodaran M, Card T, Aithal G, West J . Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology. 2006; 131(6):1752-7. DOI: 10.1053/j.gastro.2006.09.012. View

Schiefke I, Fach A, Wiedmann M, Aretin A, Schenker E, Borte G . Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005; 11(12):1843-7. PMC: 4305888. DOI: 10.3748/wjg.v11.i12.1843. View

10.

Bell H, Raknerud N, Falch J, Haug E . Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol. 1995; 132(4):444-9. DOI: 10.1530/eje.0.1320444. View

11.

Solis-Herruzo J, Castellano G, Fernandez I, Munoz R, Hawkins F . Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol. 2000; 33(5):812-7. DOI: 10.1016/s0168-8278(00)80314-1. View

12.

Peris P, Guanabens N, Pares A, Pons F, Del Rio L, Monegal A . Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int. 1995; 57(2):111-4. DOI: 10.1007/BF00298430. View

13.

Pappa H, Bern E, Kamin D, Grand R . Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol. 2008; 24(2):176-83. PMC: 3805278. DOI: 10.1097/MOG.0b013e3282f4d2f3. View

14.

Leslie W, Bernstein C, LeBoff M . AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003; 125(3):941-66. DOI: 10.1016/s0016-5085(03)01062-x. View

15.

Stellon A, Webb A, Compston J, Williams R . Low bone turnover state in primary biliary cirrhosis. Hepatology. 1987; 7(1):137-42. DOI: 10.1002/hep.1840070127. View

16.

Collier J . Bone disorders in chronic liver disease. Hepatology. 2007; 46(4):1271-8. DOI: 10.1002/hep.21852. View

17.

Benetti A, Crosignani A, Varenna M, Giussani C, Allocca M, Zuin M . Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol. 2008; 42(3):306-11. DOI: 10.1097/01.mcg.0000248017.31386.39. View

18.

Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L . Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003; 98(10):2268-74. DOI: 10.1111/j.1572-0241.2003.07639.x. View

19.

Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C . Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001; 357(9253):342-7. DOI: 10.1016/S0140-6736(00)03641-2. View

20.

Owens G, Jackson R, Lewiecki E . An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care. 2008; 13 Suppl 11:S290-308. View